Pfizer Inc. (NYSE:PFE) Shares Bought by Boothe Investment Group Inc.

Boothe Investment Group Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 18.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 269,492 shares of the biopharmaceutical company’s stock after purchasing an additional 42,773 shares during the quarter. Pfizer accounts for 3.1% of Boothe Investment Group Inc.’s investment portfolio, making the stock its 12th biggest holding. Boothe Investment Group Inc.’s holdings in Pfizer were worth $7,150,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Partners Wealth Management LLC purchased a new position in Pfizer during the 4th quarter worth $206,000. South Dakota Investment Council raised its position in Pfizer by 0.7% during the 4th quarter. South Dakota Investment Council now owns 1,348,986 shares of the biopharmaceutical company’s stock worth $35,789,000 after buying an additional 9,000 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new position in Pfizer during the 4th quarter worth $4,322,000. World Equity Group Inc. raised its position in Pfizer by 36.0% during the 4th quarter. World Equity Group Inc. now owns 89,682 shares of the biopharmaceutical company’s stock worth $2,372,000 after buying an additional 23,729 shares during the last quarter. Finally, Delta Financial Group Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at about $2,564,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Pfizer Price Performance

Pfizer stock opened at $26.32 on Monday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The stock has a market capitalization of $149.14 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The firm’s 50-day moving average is $26.30 and its two-hundred day moving average is $27.40. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.